Form 4 for CLDX Celldex Therapeutics, Inc.
Accepted 2022-08-19 00:00:00 ET · period of report 2022-08-17 · accession 0001415889-22-008896 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-08-19 | 2022-08-17+ | CLDX | Cavanaugh Sarah | SVP OF CORP AFFAIRS, ADMIN | M - OptEx | $3.04 | +32.7K | 32.6K | New | +$99.3K |
| DM | 2022-08-19 | 2022-08-17+ | CLDX | Cavanaugh Sarah | SVP OF CORP AFFAIRS, ADMIN | S - Sale+OE | $36.72 | -32.7K | 1,284 | -96% | -$1.20M |
| DM | 2022-08-19 | 2022-08-17+ | CLDX | Cavanaugh Sarah | SVP OF CORP AFFAIRS, ADMIN | M - OptEx | $0.00 | -32.7K | 10.1K | -76% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-18 | M | A | 1,355 | $9.02 | 2,639 | D | — | — | |
| 2 | Common | Common Stock | 2022-08-18 | S | D | 1,355 | $36.38 | 1,284 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.09 to $36.65 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |
| 3 | Common | Common Stock | 2022-08-17 | S | D | 31,312 | $36.73 | 1,284 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.54 to $37.05 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |
| 4 | Common | Common Stock | 2022-08-17 | M | A | 31,312 | $2.78 | 32,596 | D | — | — | (F1) Includes 876 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. |
| 5 | Derivative | Incentive Stock Option | 2022-08-17 | M | D | 31,312 | $0.00 | 10,750 | D | $2.78 · — to 2029-06-19 | 31,312 Common Stock | (F4) 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |
| 6 | Derivative | Incentive Stock Option | 2022-08-18 | M | D | 1,355 | $0.00 | 10,103 | D | $9.02 · — to 2028-06-13 | 1,355 Common Stock | (F5) As of June 13, 2022, the option is fully vested. |